January 20, 2023
Life Sciences
  • The Food and Drug Administration (FDA) rejected Eli Lilly & Co.’s attempt for accelerated approval for its Alzheimer’s therapy donanemab because not enough patients in the trial had received the drug for a full year. The company said the FDA did not identify any other deficiencies. (Article here)